Evidence map›Paper›PMID 23310947›Full record

Trial reportCancer2013

Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy.

Frank A Sinicrope, Nathan R Foster, Greg Yothers, Al Benson, Jean Francois Seitz, Roberto Labianca, Richard M Goldberg, Aimery Degramont, Michael J O'Connell, Daniel J Sargent and 1 more

Open access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 95 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
95citing papers in PubMed, 9 pooled it
7.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

95 citing papers in PubMed, 9 syntheses or guidelines pooled it, 176 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Guideline
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Article
  15. Article
  16. Nutritional indicators as predictive and prognosis biomarkers for neoadjuvant chemoradiotherapy outcomes in patients with locally advanced rectal cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Article
  17. Article
  18. Article
  19. Article
  20. Review

35 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 4 countries.

Frank A SinicropeDivision of Oncology, Mayo Clinic and North Central Cancer Treatment Group, Rochester, Minnesota, USA. sinicrope.frank@mayo.edu
Nathan R Foster
Greg Yothers
Al Benson
Jean Francois Seitz
Roberto Labianca
Richard M Goldberg
Aimery Degramont
Michael J O'Connell
Daniel J Sargent
Adjuvant Colon Cancer Endpoints (ACCENT) Group
Eastern Cooperative Oncology Group · USNorth Central Cancer Treatment Group · USNSABP Foundation · USAix-Marseille Université · FRAzienda Ospedaliero Universitaria Ospedali Riuniti · ITLeukemia Research Foundation · USMayo Clinic · US

Funding

North Central Cancer Treatment Group (NCCTG) Biospecimen ResourceU24CA114740 · NCI · MAYO CLINIC ROCHESTER · PI BUCKNER, JAN C · 2005 to 2014
$8.6M
Translational Research in Colon Cancer Prevention & TreatmentK05CA142885 · NCI · MAYO CLINIC ROCHESTER · PI SINICROPE, FRANK A. · 2009 to 2013
$808k
NCI NIH HHS CA-114740NCI NIH HHS K05 CA142885NCI NIH HHS K05CA-142885NCI NIH HHS U24 CA114740
6 · The paper itself

Abstract

backgroundAlthough obesity is an established risk factor for developing colon cancer, its prognostic impact and relation to patient sex in colon cancer survivors remains unclear.

methodsThe authors examined the prognostic and predictive impact of the body mass index (BMI) in patients with stage II and III colon carcinoma (N = 25,291) within the Adjuvant Colon Cancer Endpoints (ACCENT) database. BMI was measured at enrollment in randomized trials of 5-fluorouracil-based adjuvant chemotherapy. Association of BMI with the time to recurrence (TTR), disease-free survival (DFS), and overall survival (OS) were determined using Cox regression models. Statistical tests were 2-sided.

resultsDuring a median follow-up of 7.8 years, obese and underweight patients had significantly poorer survival compared with overweight and normal-weight patients. In a multivariable analysis, the adverse prognostic impact of BMI was observed among men but not among women (Pinteraction = .0129). Men with class 2 and 3 obesity (BMI ≥ 35.0 kg/m(2) ) had a statistically significant reduction in DFS (hazard ratio [HR], 1.16; 95% confidence interval [CI], 1.01-1.33; P = .0297) compared with normal-weight patients. Underweight patients had a significantly shorter TTR and reduced DFS (HR, 1.18; 95% CI, 1.09-1.28; P < .0001) that was more significant among men (HR, 1.31; 95% CI, 1.15-1.50; P < .0001) than among women (HR, 1.11; 95% CI, 1.01-1.23; P = .0362; Pinteraction = .0340). BMI was not predictive of a benefit from adjuvant treatment.

conclusionsObesity and underweight status were associated independently with inferior outcomes in patients with colon cancer who received treatment in adjuvant chemotherapy trials.

Indexed as

Body Mass IndexAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantColonic NeoplasmsEuropeFemaleFluorouracilHumansMaleNeoplasm StagingNorth AmericaOverweightPrognosisRandomized Controlled Trials as TopicRisk FactorsSurvival AnalysisFluorouracil

Identifiers

PMID23310947
PMCPMC3769640
OpenAlexW1709683735

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.